Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.

Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Françon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B.

CNS Drug Rev. 2003 Spring;9(1):3-20. Review.

2.

SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.

Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, Françon D, Avenet P, Depoortere H, Tan S, Oblin A, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B.

J Pharmacol Exp Ther. 2001 Aug;298(2):753-68.

PMID:
11454940
3.

R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats.

Carley DW, Depoortere H, Radulovacki M.

Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):283-9.

PMID:
11420096
4.

Autoradiographic localization of [3H]thiocolchicoside binding sites in the rat brain and spinal cord.

Balduini W, De Angelis V, Mazzoni E, Depoortere H, Cattabeni F, Cimino M.

Neuropharmacology. 2001 Jun;40(8):1044-9.

PMID:
11406196
5.

Characterization of [3H]thiocolchicoside binding sites in rat spinal cord and cerebral cortex.

Balduini W, Cimino M, Depoortere H, Cattabeni F.

Eur J Pharmacol. 1999 Jul 2;376(1-2):149-57.

PMID:
10440100
6.

Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.

Curet O, Damoiseau-Ovens G, Sauvage C, Sontag N, Avenet P, Depoortere H, Caille D, Bergis O, Scatton B.

J Affect Disord. 1998 Dec;51(3):287-303. Review.

PMID:
10333983
7.

The Pharmacology and Mechanism of Action of Zolpidem.

Sanger DJ, Depoortere H.

CNS Drug Rev. 1998 Dec;4(4):323-340. doi: 10.1111/j.1527-3458.1998.tb00074.x. No abstract available.

8.

Neuroprotective effects of eliprodil in a rat hippocampal slice hypoxia model.

Santamaria R, Françon D, Depoortere H, Scatton B.

Ann N Y Acad Sci. 1997 Oct 15;825:232-8. No abstract available.

PMID:
9369990
9.

Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes.

Avenet P, Léonardon J, Besnard F, Graham D, Depoortere H, Scatton B.

Neurosci Lett. 1997 Feb 21;223(2):133-6.

PMID:
9089691
10.

Development of stable cell lines expressing different subtypes of GABAA receptors.

Besnard F, Even Y, Itier V, Granger P, Partiséti M, Avenet P, Depoortere H, Graham D.

J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):99-113.

PMID:
9029483
11.

Protracted treatment with diazepam reduces benzodiazepine1 receptor-mediated potentiation of gamma-aminobutyric acid-induced currents in dissociated rat hippocampal neurons.

Itier V, Granger P, Perrault G, Depoortere H, Scatton B, Avenet P.

J Pharmacol Exp Ther. 1996 Dec;279(3):1092-9.

PMID:
8968329
12.

Zolpidem functionally discriminates subtypes of native GABAA receptors in acutely dissociated rat striatal and cerebellar neurons.

Itier V, Depoortere H, Scatton B, Avenet P.

Neuropharmacology. 1996 Feb;35(2):137-45.

PMID:
8734481
13.

Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes.

Avenet P, Léonardon J, Besnard F, Graham D, Frost J, Depoortere H, Langer SZ, Scatton B.

Eur J Pharmacol. 1996 Jan 25;296(2):209-13.

PMID:
8838458
14.

Block of P-type Ca2+ channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells.

Biton B, Granger P, Depoortere H, Scatton B, Avenet P.

Eur J Pharmacol. 1995 Dec 27;294(1):91-100.

PMID:
8788420
15.

Differential effects of midazolam and zolpidem on sleep-wake states and epileptic activity in WAG/Rij rats.

Depoortere H, Françon D, van Luijtelaar EL, Drinkenburg WH, Coenen AM.

Pharmacol Biochem Behav. 1995 Aug;51(4):571-6.

PMID:
7675828
16.

Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin.

Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, Langer SZ, Scatton B, Avenet P.

Mol Pharmacol. 1995 Jun;47(6):1189-96.

PMID:
7603459
17.

Mizolastine, a novel selective histamine H1 receptor antagonist: lack of sedative potential on the EEG in the rodent.

Depoortere H, Decobert M, Granger P, Françon D.

Neuropsychobiology. 1995;32(4):214-21.

PMID:
8587704
18.

The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca2+ channels in rat cultured cortical neurons.

Biton B, Granger P, Carreau A, Depoortere H, Scatton B, Avenet P.

Eur J Pharmacol. 1994 May 23;257(3):297-301.

PMID:
8088348
19.

Influence of zolpidem, a novel hypnotic, on the intermediate-stage and paradoxical sleep in the rat.

Gottesmann C, Trefouret S, Depoortere H.

Pharmacol Biochem Behav. 1994 Feb;47(2):359-62.

PMID:
8146229
20.

Evaluation of the stability and quality of sleep using Hjorth's descriptors.

Depoortere H, Francon D, Granger P, Terzano MG.

Physiol Behav. 1993 Oct;54(4):785-93.

PMID:
8248358
21.

Effects of a magnesium-deficient diet on sleep organization in rats.

Depoortere H, Françon D, Llopis J.

Neuropsychobiology. 1993;27(4):237-45.

PMID:
8232845
22.

Imidazopyridines: towards novel hypnotic and anxiolytic drugs.

George P, Rossey G, Depoortere H, Mompon B, Allen J, Wick A.

Farmaco. 1991 Jan;46(1 Suppl):277-88. Review. No abstract available.

PMID:
1677245
23.

Intraperitoneal cholecystokinin-8 induces atypical somnolence and EEG changes.

Depoortere H, De Saint-Hilaire Z, Nicolaïdis S.

Physiol Behav. 1990 Dec;48(6):873-7.

PMID:
2087520
24.

Modifications of sleep structure induced by increasing levels of acoustic perturbation in normal subjects.

Terzano MG, Parrino L, Fioriti G, Orofiamma B, Depoortere H.

Electroencephalogr Clin Neurophysiol. 1990 Jul;76(1):29-38.

PMID:
1694482
25.

[A specific domain (the omega 1 site) of the GABA(A) receptor may be implicated in the hypnotic effects of zolpidem].

Benavides J, Depoortere H, Sanger D, Perrault G, Arbilla S, Langer SZ, Zivkovic B, Scatton B.

Encephale. 1990 Jan-Feb;16(1):13-22. Review. French.

PMID:
2158421
26.

Does cholecystokinin induce physiological satiety and sleep?

de Saint Hilaire-Kafi Z, Depoortere H, Nicolaïdis S.

Brain Res. 1989 May 29;488(1-2):304-10.

PMID:
2743125
27.

Pharmacokinetics, brain distribution and pharmaco-electrocorticographic profile of zolpidem, a new hypnotic, in the rat.

Garrigou-Gadenne D, Burke JT, Durand A, Depoortere H, Thénot JP, Morselli PL.

J Pharmacol Exp Ther. 1989 Mar;248(3):1283-8.

PMID:
2703975
28.

Aspects of sleep-wakefulness architecture by computer analysis in cats.

Granger P, Depoortere H.

Neuropsychobiology. 1988;19(4):212-6.

PMID:
3247018
29.

Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile.

Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G.

J Pharmacol Exp Ther. 1987 Apr;241(1):245-50.

PMID:
3033203
30.
31.

Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.

Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, Bartholini G.

J Pharmacol Exp Ther. 1986 May;237(2):649-58.

PMID:
2871178
32.

Hypnotics: clinical value of pharmaco-EEG methods.

Depoortere H, Decobert M, Granger P, Riou-Merle F.

Neuropsychobiology. 1986;16(2-3):157-62.

PMID:
2884592
33.

Non-benzodiazepine anxiolytics: potential activity of phenylpiperazines without 3H-diazepam displacing action.

Lloyd KG, Depoortere H, Scatton B, Schoemaker H, Zivkovic B, Manoury P, Langer SZ, Morselli PL, Bartholini G.

Pharmacol Biochem Behav. 1985 Oct;23(4):645-52.

PMID:
2866545
34.

Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats.

Arbilla S, Depoortere H, George P, Langer SZ.

Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):248-51.

PMID:
2997631
35.

The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials.

Lloyd KG, Morselli PL, Depoortere H, Fournier V, Zivkovic B, Scatton B, Broekkamp C, Worms P, Bartholini G.

Pharmacol Biochem Behav. 1983 Jun;18(6):957-66.

PMID:
6351106
36.

Drug effects on the EEG of various species of laboratory animals.

Depoortere H, Decobert M, Honoré L.

Neuropsychobiology. 1983;9(4):244-9. Review.

PMID:
6358940
37.

gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra.

Worms P, Depoortere H, Durand A, Morselli PL, Lloyd KG, Bartholini G.

J Pharmacol Exp Ther. 1982 Mar;220(3):660-71.

PMID:
6278129
38.

alpha-Adrenoceptive influences on hippocampal theta rhythm in the rat.

Monmaur P, Depoortere H, M'Harzi M.

Behav Neural Biol. 1981 Sep;33(1):129-32. No abstract available.

PMID:
6119977
39.

[Experimental electropharmacologic studies of cerebral ischemia (author's transl)].

Depoortere H.

Rev Electroencephalogr Neurophysiol Clin. 1981 Jul-Sep;10(3):207-14. French.

PMID:
7302319
40.

Rapid-eye-movement sleep deprivation decreases the density of 3H-dihydroalprenolol and 3H-imipramine binding sites in the rat cerebral cortex.

Mogilnicka E, Arbilla S, Depoortere H, Langer SZ.

Eur J Pharmacol. 1980 Jul 25;65(2-3):289-92.

PMID:
7398791
41.

Some aspects of the polygraphic studies on sleep-wakefulness cycle in rat.

Depoortere H.

Waking Sleeping. 1980 Jan-Mar;4(1):47-62.

PMID:
7395195
42.

Neuropharmacological spectrum of muscimol.

Worms P, Depoortere H, Lloyd KG.

Life Sci. 1979 Aug 13;25(7):607-14. No abstract available.

PMID:
574181
43.

Changes in the rat electrocorticogram following administration of two dihydrogenated ergot derivatives.

Carruthers-Jones DI, Depoortere H, Loew DM.

Gerontology. 1978;24 Suppl 1:23-33.

PMID:
412729
44.

[Alerting effect of vincamine in rats (author's transl)].

Depoortere H, Rousseau A, Jalfre M.

Rev Electroencephalogr Neurophysiol Clin. 1977 Apr-Jun;7(2):153-7. French.

PMID:
594456
45.

[Effect of vincamine on sleep-wakefulness equilibrium in the cat (author's transl)].

Da Costa LM, Depoortere H, Naquet R.

Rev Electroencephalogr Neurophysiol Clin. 1977 Apr-Jun;7(2):158-64. French.

PMID:
201975
46.

Effects of dihydrogenated ergot alkaloids on the sleep-wakefulness cycle and on brain biogenic amines in the rat.

Loew DM, Depoortere H, Buerki HR.

Arzneimittelforschung. 1976;26(6):1080-3.

PMID:
822856
47.

Neuropharmacological studies on hydergine.

Depoortere H, Loew DM, Vigouret JM.

Triangle. 1975;14(2):73-9. No abstract available.

PMID:
812222
48.
49.

Alterations in sleep-wakefulness cycle in rats following treatment with (+)-lysergic acid diethylamide (LSD-25).

Depoortere H, Loew DM.

Br J Pharmacol. 1971 Feb;41(2):402P-403P. No abstract available.

50.

[Effects of D-lysergic acid diethylamide (LSD-25) and 2-bromo-D-lysergic acid diethylamide (BOL-148) on sleeping behavior in rats].

Loew DM, Depoortere H, Vigouret JM.

Naunyn Schmiedebergs Arch Pharmakol. 1970;266(4):394-5. German. No abstract available.

PMID:
4326420

Supplemental Content

Loading ...
Support Center